Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856081 | 0.88 | HDAC3 (0.43) | MAPK14IDH1HDAC3HDAC1HDAC2 | |
| SCHEMBL4857398 | 0.88 | MAPK14 (0.37) | MAPK14FGFR1MAPK13MAPK12MAPK11 | |
| SCHEMBL4857416 | 0.88 | MAPK14 (0.37) | MAPK14FGFR1MAPK13MAPK12MAPK11 | |
| SCHEMBL4848540 | 0.87 | MAPK14 (0.46) | MAPK14FGFR1MAPK13MAPK12MAPK11 | |
| SCHEMBL4848543 | 0.87 | MAPK14 (0.46) | MAPK14FGFR1MAPK13MAPK12MAPK11 | |
| SCHEMBL4853908 | 0.85 | MAPK14 (0.44) | MAPK14NTRK1IDH1FGFR1HDAC3 | |
| SCHEMBL4858023 | 0.85 | MAPK14 (0.47) | MAPK14FGFR1MAPK13MAPK12MAPK11 | |
| SCHEMBL4847893 | 0.78 | MAPK14 (0.51) | MAPK14MAPK11MAPK1 | |
| SCHEMBL4852870 | 0.75 | FGFR1 (0.38) | MAPK14FGFR1MAPK13MAPK12MAPK11 | |
| SCHEMBL4852879 | 0.75 | FGFR1 (0.38) | MAPK14FGFR1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | claimed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | DPYD, IL1B, IL6 | MAPK14 2806/4885NTRK1 4653/4885IDH1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.